Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegenzileukin with or without pembrolizumab in relapsed/refractory B-cell lymphoma
NCT05179603Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 2, open-label trial of pegenzileukin in classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Sanofi. Primary endpoint: Complete Response Rate at 21 months. Started Dec 2021; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
classic Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05179603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179603.